Impact of the moderate CYP3A4 inhibitor diltiazem on the single-dose pharmacokinetics of the dual orexin receptor antagonist act-541468

Authors
Category Primary study
ConferenceClinical Pharmacology and Therapeutics
Year 2018
This article has no abstract
Epistemonikos ID: b15dc80c9a01971291a29decfc4d4c64decb1f77
First added on: Apr 29, 2026